Key Takeaways
- Formation Bio has signed a licensing deal with Sanofi potentially worth 545 million euros ($626 million) for its oral dual JAK/SYK inhibitor, gusacitinib.
- Gusacitinib is currently in phase 3 trials for chronic hand eczema, and Sanofi plans to investigate its use for a new indication.
- Formation Bio aims to enhance drug development efficiency through partnerships and innovative AI solutions.
License Agreement with Sanofi
Formation Bio, a biotech company focused on artificial intelligence and drug development, has secured a significant licensing agreement with Sanofi that could reach up to 545 million euros (approximately $626 million). This deal, which includes upfront fees and milestone payments, grants Sanofi access to Formation’s oral dual JAK/SYK inhibitor, gusacitinib. While specific financial details were not disclosed, the collaboration marks a significant advancement for both companies.
Gusacitinib is currently in phase 3 of development for chronic hand eczema. However, Sanofi intends to explore the drug’s potential in a new indication that has not yet been assessed in a phase 1 study. “This transaction with Sanofi ushers gusacitinib into its next stage of development,” stated Formation, highlighting Sanofi’s capability to leverage its global expertise in drug development and commercialization.
Formation Bio’s strategy revolves around acquiring high-potential drug assets, rapidly unlocking their value, and forming partnerships at pivotal stages. CEO Benjamine Liu emphasizes the company’s commitment to innovation, stating, “We’re proud to have Sanofi as a world-class partner working together to accelerate innovation in medicine.”
The acquisition of gusacitinib from Asana BioSciences took place in 2022 and included another compound, ASN008, which is currently in phase 2 trials for treating notalgia paresthetica and itch associated with atopic dermatitis. This strategic expansion reflects Formation’s focus on enhancing its clinical pipeline.
In addition to its core developments, Formation Bio raised $372 million in a series D funding round in June 2024, a significant portion of which was earmarked for expanding its clinical pipeline. The company has a unique business model that involves collaborating with other drug developers to streamline workflow automation. This includes creating tailored patient recruitment content for specific clinical trial cohorts and quickly generating AI-generated adverse event reports.
Sanofi not only invested in Formation’s series D funding but is also actively collaborating on a project aimed at developing an AI-powered tool to enhance drug development processes, particularly in accelerating clinical trial recruitment. This partnership between Formation Bio and Sanofi highlights a growing trend in the pharmaceutical industry—leveraging AI technology to improve developmental efficiency and patient outcomes, setting new standards for how drugs are developed and brought to market.
Overall, this licensing agreement signifies a strategic alliance that could potentially benefit both Formation Bio and Sanofi, contributing to advancements in medical treatments while enhancing collaborative efforts in drug development.
The content above is a summary. For more details, see the source article.
